Foster Dykema Cabot & Partners, LLC Royalty Pharma PLC Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.19 Trillion
- Q3 2024
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Royalty Pharma PLC stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 121 shares of RPRX stock, worth $3,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121Holding current value
$3,839% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RPRX
# of Institutions
415Shares Held
282MCall Options Held
578KPut Options Held
47.5K-
Morgan Stanley New York, NY41.1MShares$1.3 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$1.19 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$730 Million0.01% of portfolio
-
Baillie Gifford & CO14.1MShares$448 Million0.28% of portfolio
-
Swedbank Ab Stockholm, V712.2MShares$386 Million0.39% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $13.9B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...